Selectively partner with leading pharmaceutical companies to harness the full potential of our platform while retaining product rights in key markets, and work closely with patient advocacy groups to inform our programs.
We have entered into strategic partnerships with biopharmaceutical companies in order to maximize the potential of the platform and broaden our therapeutic reach through their expertise and commercial capabilities.
Our partnership with Roche is focused on the design, development and commercialization of targeted and proprietary AAV products for use in ophthalmology indications. Initial products in development will be targeted to address inherited retinal diseases, using 4DMT intravitreal injection vectors, including for the treatment of Choroideremia (4D-110). 4DMT will focus on product design and engineering, preclinical development, early-stage clinical development (Phase 1-2 trials) and pre-commercial manufacturing and analytical activities. Roche is positioned to perform pivotal Phase 3 trials, regulatory and pricing approval activities, and global commercialization. Roche will fund all R&D activities performed by 4DMT on Roche-licensed products, including development through Phase 2 clinical trials for Choroideremia.
Under the agreement, Roche has an exclusive, sublicenseable, worldwide license to develop and commercialize products and constructs using our proprietary AAV vectors to treat ophthalmological diseases and disorders, excluding treatment and prevention of cancer and central nervous system conditions (but not retinal nerves) and delivery of DNA-directed RNA interference.